Use of Citrus bergamia Essential Oil in the management of Stress and Anxiety in public school teachers in the city of Lajedo-PE: A single-blind randomized clinical trial

Start Date16 Mar 2025

Sponsor / Collaborator

Fundação Universidade de Pernambuco

[+1]

RBR-2kms8f9

/ Not yet recruitingNot ApplicableIIT

Sleep disorders and associated factors in children and adolescents in the metropolitan region of Recife

Start Date01 Feb 2025

Sponsor / Collaborator

Universidade de Pernambuco

[+1]

RBR-9mj5ymr

/ SuspendedNot ApplicableIIT

Effects of Physical Exercise pre and post surgery on health outcomes of Metabolic and Bariatric Surgery patients

Start Date01 Nov 2024

Sponsor / Collaborator

Universidade de Pernambuco

100 Clinical Results associated with Universidade de Pernambuco

0 Patents (Medical) associated with Universidade de Pernambuco

9,274

Literatures (Medical) associated with Universidade de Pernambuco

01 Jul 2025·Gait & Posture

Effects of a 24-week dual-task training on postural control complexity during standing and walking in older adults: Secondary analysis from a randomized controlled trial

Article

Author: Brito, Victória Alves de ; Trombini-Souza, Francis ; Leal, Iara Dos Santos ; Rodrigues, Lucas Martins ; Alencar, Júlia Gomes de

BACKGROUNDFunctional decline in gait motor control and the capacity to maintain balance during upright standing posture in older adults is influenced by deterioration in the complexity of various physiological systems involved in these daily activities.RESEARCH QUESTIONIs a 24-week dual-task protocol training, beginning with alternating cognitive demands and progressing to simultaneous dual-tasking, more effective than a control group training only with alternating dual tasks in improving the physiological complexity of postural control in older adults during upright standing posture under interoceptive and exteroceptive demands and gait under dual tasks?METHODSThis randomized controlled trial enrolled 60 community-dwelling older adults of both sexes, aged between 60 and 80. The experimental group (EG; n = 30) underwent training with progression from alternating dual-task (ADT) to simultaneous dual task (SDT) during activities such as gait, and static and dynamic functional balance. The control group (CG; n = 30) only underwent the ADT protocol throughout the six months of training. The primary outcome of this study was the physiological complexity of gait under dual task calculated by the refined composite multiscale fuzzy entropy method for the anteroposterior (AP), mediolateral (ML), and vertical (V) directions. The outcomes were acquired at baseline (T1) and after 24 weeks of intervention (T2). The analyses were based on the intention-to-treat principle, using generalized linear mixed models (GLMM) with a significance level of 5 %.RESULTSNo interaction or group effects were observed. However, both groups significantly improved body sway physiological complexity in the AP direction during gait under ST, ADT, and SDT and in the V direction under ADT and SDT. No change in complexity during upright standing posture under interoceptive and exteroceptive demand was significantly observed, regardless of the group.SIGNIFICANCERegardless of the training protocol, both groups significantly improved the physiological complexity of gait under dual task.

01 May 2025·Neurochirurgie

Endoscopic transorbital approach for the management of spheno-orbital meningiomas: A systematic review and meta-analysis

Article

Author: Ferreira, Marcio Yuri ; Fukunaga, Christian Ken ; Neto, Ary Rodrigues ; Nogueira, Bernardo Vieira ; Filho, Helvécio Neves Feitosa ; Sousa, Marcelo Porto ; Garcia, Guilherme Cristiano ; Polverini, Allan Dias ; Brito, Herika Negri ; Montecino, Laura Mora ; Palavani, Lucca B ; Andreão, Filipi Fim ; Ribeiro, Filipe Virgilio

INTRODUCTIONMeningioma is the most common benign tumor in the central nervous system and may arise from the sphenoid wing region. The tumor can involve the cavernous sinus medially, periorbital and orbital apex structures anteriorly, and infratemporal fossa inferiorly. Surgical approaches more currently used include the fronto-temporal approach, the pterional approach, and even the frontotemporal-orbitozygomatic approach. The results of safety and efficacy of Transorbital neuroendoscopic surgery for these cases are still unclear, with scarce literature on the subject.OBJECTIVEWe assessed the safety and efficacy of Endoscopic Transorbital Approach (TOA) for the Management of Spheno-Orbital Meningiomas (SOMs).METHODSWe searched Medline, Embase, Web of Science databases following PRISMA guidelines. We used single proportion analysis with 95% confidence intervals under a random-effects model, I² to assess heterogeneity, and Baujat and sensitivity analysis to address high heterogeneity. Eligible studies included those with ≥4 patients treated with endoscopic transorbital approach for the management of spheno-orbital meningioma.RESULTSOf the 3520 studies initially identified, 9 were selected, involving 216 patients, with a median follow-up of 20 months. For subtotal resection, pooled analysis confirmed a rate of 40% (CI: 24% to 57%) and a total resection rate of 46% (CI: 27% to 65%). The analysis also confirmed a rate of visual deficits of 10% (CI: 0% to 24%). The rate of cerebrospinal fluid leak was 2% (CI: 0% to 5%), and diplopia occurred in 8% of cases (CI: 0% to 18%).CONCLUSIONETOA is a safe and minimally invasive approach for spheno-orbital meningiomas, with low complication rates and effective cranial nerve preservation. However, its tumor resection efficacy is inferior to non-minimally invasive techniques, potentially affecting long-term outcomes. Further studies are needed to clarify its role and optimize tumor control in selected cases.

01 May 2025·American Journal of Obstetrics & Gynecology MFM

Postpartum furosemide for accelerating recovery in patients with preeclampsia: a randomized placebo-controlled trial

Article

Author: Amorim, Melania ; Silva, Thais Valeria ; Coutinho, Isabela ; Cursino, Telma ; Cunha, Anna Catharina Carneiro da ; de Souza, Alex Sandro Rolland ; Katz, Leila

BACKGROUNDPreeclampsia is a major hypertensive disorder of pregnancy that may lead to severe complications, particularly in the first 2 weeks of the postpartum period. Blood pressure during the postpartum period remains high and often increases to levels higher than those observed during pregnancy. Furosemide, a fast-acting diuretic, reduces intravascular volume overload and may represent an alternative to accelerate the normalization of blood pressure levels.OBJECTIVEThis study aimed to evaluate the effectiveness of furosemide compared with a placebo for blood pressure control in the postpartum period in women with severe preeclampsia.STUDY DESIGNIn a triple-masked placebo-controlled randomized clinical trial, postpartum women with de novo preeclampsia with severe features or eclampsia diagnosed during pregnancy and adequate diuresis who had received magnesium sulfate were randomized to receive furosemide (40 mg/d orally for 5 days) or a placebo. The primary outcome was mean blood pressure. The secondary outcomes were frequency of severe hypertensive episodes, continued need for antihypertensives, number of antihypertensives used to control blood pressure, length of hospital stay, adverse effects, and maternal complications. A sample size of 120 patients was estimated, 60 in each arm of the study, based on the estimated difference between the mean systolic pressure of 142±12 mm Hg for the furosemide group and 153±19 mm Hg for the placebo group.RESULTSBetween June 20, 2014, and November 30, 2014, 271 women were screened, and 120 were randomized to the furosemide or placebo groups, of which 118 were included in the final analysis (58 in the furosemide group and 60 in the placebo group). Most characteristics were similar between the groups. The mean daily systolic and diastolic pressures were lower in the furosemide group (P<.001), and there were fewer episodes of severe hypertension on the second (P=.04) and fifth (P=.04) days of the postpartum period. In addition, a shorter time was required until blood pressure was controlled (P=.01) in the furosemide group.CONCLUSIONCompared with placebo, 40 mg/d of oral furosemide in patients with preeclampsia reduced the mean daily systolic blood pressure in the first and fifth days of the postpartum period and mean daily diastolic blood pressure in the first, second, and fifth days of the postpartum period and the time required for blood pressure control.

100 Deals associated with Universidade de Pernambuco

100 Translational Medicine associated with Universidade de Pernambuco

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 30 May 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Universidade de Pernambuco

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 30 May 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing